Although the therapeutic effects were observed in both monotherapies, especially the robust therapeutic effect of ZD55-IL-24 therapy alone, the combined therapy further slowed the growth of established B16 melanomas compared with either therapy alone (Fig. 1b). The gene discussed is IL24; the disease is melanoma.